2. Progression of Hepatitis B Infection Short-term Infection Long-term Hepatitis Cirrhosis 30 - 50 Years Liver Cancer Death Long-term Carrier Resolution Cirrhosis Resolution Death Silent Cirrhosis

3. Hepatic Fibrosis Cirrhosis Liver Cancer Healthy Liver

4. Hepatic Fibrosis Cirrhosis Liver Cancer Healthy Liver

10. How the Infection is Acquired in the West? Transfusion and transplant recipients Individuals with multiple sexual partners Healthcare workers Newborns of long-term carriers Intravenous drug users Prisoners and other institutionalised people

11. Where Are the Long-term HBV Carriers? Percentage long-term HBV carriers (350 million long-term carriers): < 2% - Low 2-7% - Intermediate > 8% - High Margolis et al. 1991

29. Detection of serologic markers of hepatitis B virus (HBV) infection, as a function of time, in acute cases.

30. The Efficacy and Safety of Lamivudine in HBeAg-positive Chronic Hepatitis B Return to Main Index Enter

37. Lamivudine Rapidly Suppresses Serum HBV DNA Study Week Median % Change 0 10 20 30 40 50 Schiff Dienstag Lai Dienstag Schiff Lai Schalm Lamivudine -100 -80 -60 -40 -20 0 10 Placebo

38. Lamivudine Leads to HBeAg Seroconversion (HBeAg-, Anti-HBe+) Lamivudine + IFN 6 7 21 0 5 10 15 20 25 30 Placebo Lamivudine IFN Lai Dienstag Schalm *p<0.04 compared to placebo Patients (%) 13 14 Schiff 29 * 17 * 20 21 20

42. Concurrent immunologic diseases in type 1 autoimmune hepatitis.

43. Probabilities of clinical, biochemical, and histologic remission during corticosteroid therapy.